|Dr. Severin Schwan||CEO & Exec. Director||N/A||N/A||1967|
|Dr. Alan Hippe||Chief Financial & Information Officer||N/A||N/A||1967|
|Dr. Gottlieb A. Keller||Gen. Counsel & Corp. Sec.||N/A||N/A||1954|
|Ms. Cristina A. Wilbur||Head of Group HR||N/A||N/A||1967|
|Dr. Karl Mahler||Head of Investor Relations||N/A||N/A||N/A|
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases. The company's diagnostic solutions include blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol and coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis, heterogeneous immunochemistry, homogeneous immuno assay, immunology, and infectious disease solutions; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control services; real-time PCR diagnostic systems; urinalysis; and serum work area and workflow solutions. In addition, it offers gene expression, gene sequencing, and real time PCR systems for researchers. The company licenses its products or technologies to third parties. Roche Holding AG has a collaboration agreement with San Francisco-based Syapse to develop software that integrates fragmented clinical, molecular, and data on treatment plans and health outcomes. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 8.